A clinically supported early-stage treatment addressing an often overlooked and undertreated men’s health condition.
IBSA UK&I has confirmed the launch of Perovial®, the first licensed injectable hyaluronic acid treatment specifically indicated for the management of Peyronie’s disease (PD in its acute phase.
Perovial® expands the treatment landscape by offering clinicians an evidence-based option for men presenting early in the disease course, helping to close long-standing gaps in the management of Peyronie’s disease.
Peyronie’s disease is a progressive condition marked by penile curvature, pain, deformity and erectile dysfunction, driven by fibrotic plaque development within the tunica albuginea. Prevalence estimates suggest between 0.3% and 13.1% of men worldwide are affected, although true figures are likely underestimated due to delayed presentation, stigma and underdiagnosis. Approximately 60% of men with Peyronie’s disease report a reduced quality of life, and therapeutic options during the acute phase remain limited and inconsistently incorporated into treatment pathways.
Identifying the condition early is crucial. The acute phase is characterised by active inflammation and evolving symptoms, presenting a potential window for intervention to help limit long-term scarring and deformity. However, limited awareness of Peyronie’s disease continues to pose a barrier to early diagnosis and timely treatment.
A new injectable pathway for acute phase management
Perovial® is delivered via intrapenile injection over a 10–12-week treatment course6. The hyaluronic acid formulation with its antioxidative and antifibrotic properties is designed to soften plaque and support tissue remodelling, helping to slow or limit the progression of scarring.
Clinical studies report improvements in penile curvature, plaque size and erectile function, with favourable patient satisfaction and a tolerable safety profile.
As the first hyaluronic acid injectable licensed for Peyronie’s disease in the UK, Perovial® provides clinicians with a clear, accessible and structured intervention option ahead of chronic-stage surgical pathways. It also offers an alternative to other potential treatments with variable evidence bases, supporting a more consistent standard of care for patients.
Professor David Ralph, Professor of Urology, University College London, St Peter’s Andrology, and a UK urology Andrologist said: “Peyronie’s disease is often misunderstood, underdiagnosed and undertreated, partly because many men delay seeking help and partly because clinicians have had limited options to offer during the acute phase. The availability of a licensed hyaluronic acid injectable such as Perovial® provides a much-needed structured pathway for early intervention. Improving recognition of the acute phase and providing accessible treatment choices which could make a significant difference to long-term outcomes for many patients.”
Kevin, a patient living with Peyronie’s disease said: “Peyronie’s disease quietly crept into every part of my life and put real pressure on my relationship. I didn’t talk about it because I genuinely didn’t know where to turn, and that silence was incredibly isolating. Looking back, if I’d understood that the early signs needed prompt attention, I would have acted much sooner. Knowing there’s now a licensed treatment available in the early stages means men don’t have to sit in silence or wait until things worsen.”
